Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Methylprednisolone sodium succinate
Drug ID BADD_D01436
Description A water-soluble ester of methylprednisolone used for cardiac, allergic, and hypoxic emergencies.
Indications and Usage Not Available
Marketing Status approved
ATC Code Not Available
DrugBank ID DB14644
KEGG ID D00751
MeSH ID D008776
PubChem ID 23680530
TTD Drug ID Not Available
NDC Product Code 0404-9957; 71872-7061; 0009-0003; 0009-0047; 0143-9754; 43598-129; 0009-0698; 52584-039; 52584-047; 0009-0850; 55150-263; 55154-3940; 55154-3941; 63323-255; 43598-128; 70518-2023; 0143-9850; 63323-265; 0404-9958; 71872-7232; 55150-262; 55150-265; 70518-3684; 0009-0039; 0143-9753; 71872-7085; 0143-9851; 55154-3939; 55154-3944; 43598-127; 50090-0271; 63323-258; 0009-0018; 43598-130; 0009-0758; 55150-264
UNII LEC9GKY20K
Synonyms Methylprednisolone Hemisuccinate | Hemisuccinate, Methylprednisolone | Methylprednisolone Succinate | Succinate, Methylprednisolone | Urbason-Soluble | UrbasonSoluble | Solu-Medrol | Solumedrol | A-MethaPred | Methylprednisolone Sodium Succinate | Sodium Succinate, Methylprednisolone | Methylprednisolone Hemisuccinate Monosodium Salt | 6 alpha-Methylprednisolone Sodium Hemisuccinate | Methylprednisolone Sodium Hemisuccinate | Sodium Hemisuccinate, Methylprednisolone
Chemical Information
Molecular Formula C26H33NaO8
CAS Registry Number 2375-03-3
SMILES CC1CC2C3CCC(C3(CC(C2C4(C1=CC(=O)C=C4)C)O)C)(C(=O)COC(=O)CCC(=O)[O-])O.[Na+]
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Glycosuria20.02.01.005--
Headache17.14.01.001--
Hepatomegaly09.01.05.001--Not Available
Hiccups22.12.01.001; 07.01.06.009--
Hirsutism05.05.01.005; 23.02.04.001--
Hyperhidrosis08.01.03.028; 23.02.03.004--
Hypersensitivity10.01.03.003--
Hypertension24.08.02.001--
Hypertrichosis23.02.04.002--
Hypertrophic cardiomyopathy03.07.07.005; 02.04.01.002--Not Available
Hypokalaemic syndrome14.05.03.003--Not Available
Hypopituitarism05.03.02.001--
Impaired healing08.03.02.001--Not Available
Increased appetite14.03.01.003; 08.01.09.027--Not Available
Increased insulin requirement14.06.01.006; 05.06.01.006--Not Available
Infection susceptibility increased10.02.01.046; 11.01.08.004--Not Available
Injection site infection12.07.03.008; 11.01.08.005; 08.02.03.019--Not Available
Insomnia19.02.01.002; 17.15.03.002--
Intracranial pressure increased17.07.02.002--Not Available
Intraocular pressure increased13.07.04.002--Not Available
Large intestine perforation12.02.03.005; 07.04.06.005--
Malaise08.01.01.003--
Menstruation irregular21.01.01.005; 05.05.01.008--
Mood swings19.04.03.001--Not Available
Muscle disorder15.05.03.014--Not Available
Muscular weakness15.05.06.001; 17.05.03.005--
Myocardial infarction24.04.04.009; 02.02.02.007--
Myocardial rupture12.01.11.002; 02.04.02.002--Not Available
Myopathy15.05.05.001--Not Available
Nausea07.01.07.001--
The 2th Page    First    Pre   2 3 4    Next   Last    Total 4 Pages